Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Patil et al. Investigation of <i>Cannabis sativa</i> Phytochemicals as Anti-Alzheimer's Agents: An In Silico Study. <i>Plants</i> 2023, <i>12</i>, 510.

Plants (Basel, Switzerland)·2026
Same author

A Novel <i>De Novo</i> Assembly Approach for Transcriptome Profiling and Marker Identification in <i>Grewia Asiatica</i> (Phalsa), a Medicinal Plant, Across Leaf And Root Tissues.

Current genomics·2026
Same author

GLP-1 and the brain's powerhouse: a new perspective on the role of mitochondria in neuroprotection.

Metabolic brain disease·2026
Same author

Exploring the chemical diversity of Dictyostelium secondary metabolites and their biological implications.

Archives of microbiology·2026
Same author

Cell-free systems for low-cost diagnostics.

Progress in molecular biology and translational science·2026
Same author

Cell free systems for biodesign.

Progress in molecular biology and translational science·2026

Related Experiment Video

Updated: May 23, 2026

Sustained Administration of &#946;-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

Long-acting peptidomimetics based DPP-IV inhibitors.

Pradip Jadav1, Rajesh Bahekar, Shailesh R Shah

  • 1Zydus Research Centre, Sarkhej-Bavla NH 8A Moraiya, Ahmedabad, India.

Bioorganic & Medicinal Chemistry Letters
|April 17, 2012
PubMed
Summary

New pyrrolidine-based peptidomimetics show promise as potent and selective dipeptidyl peptidase-IV (DPP-IV) inhibitors. The lead compound 16c demonstrated sustained antihyperglycemic effects and an improved pharmacokinetic profile for type 2 diabetes treatment.

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Related Experiment Videos

Last Updated: May 23, 2026

Sustained Administration of &#946;-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Endocrinology

Background:

  • Dipeptidyl peptidase-IV (DPP-IV) inhibitors are a key therapeutic class for managing type 2 diabetes mellitus (T2DM).
  • Developing novel DPP-IV inhibitors with improved efficacy and pharmacokinetic properties remains an active area of research.

Purpose of the Study:

  • To design and synthesize novel pyrrolidine-based peptidomimetics as potential DPP-IV inhibitors.
  • To evaluate the in vitro potency, selectivity, and in vivo antihyperglycemic effects of these compounds.

Main Methods:

  • Synthesis of pyrrolidine-based peptidomimetics.
  • In vitro enzyme inhibition assays to determine DPP-IV inhibitory activity and selectivity.
  • In vivo studies to assess antihyperglycemic effects and pharmacokinetic profiles in a T2DM model.

Main Results:

  • Compounds 16c and 16d exhibited potent and selective inhibition of DPP-IV in vitro.
  • The lead compound, 16c, demonstrated sustained antihyperglycemic effects in vivo.
  • Compound 16c also displayed an improved pharmacokinetic profile compared to existing treatments.

Conclusions:

  • Pyrrolidine-based peptidomimetics represent a promising scaffold for the development of novel DPP-IV inhibitors.
  • Compound 16c warrants further investigation as a potential therapeutic agent for T2DM due to its efficacy and favorable pharmacokinetics.